Martindale Pharma improves Aurum pre-filled syringe packaging

Published: 9-Nov-2011
Packaging Regulatory

To ensure ease of use and improve patient safety

Martindale Pharma, a UK manufacturer and supplier of pharmaceutical specials, has made a number of improvements to its Aurum range of 11 pre-filled syringes.

The Aurum syringes are used for on-the-spot administration of drugs where high visibility and simple drug identification is crucial.

The Brentwood, Essex-based firm has redesigned the range to enhance ease of use and help improve patient safety. Specific improvements include new colour-differentiated packaging; colour-differentiated translucent boxes that confirm contents; and colour-differentiated labels. In addition the firm has improved tamper-evident labels and the packaging is latex-free and Luer Lock fitting.

The firm says its new colour-differentiated packaging meets national and international colour differentiation standards on syringe labelling and also the Royal College of Anaesthetists recommendations on syringe labelling in critical care.

See more

You may also like

Manufacturing

Navigating SOE compliance: how to strengthen organic enforcement within your organisation

Read more
Part I of NSF’s webinar series explores strategies to meet rising regulatory demands, reduce fraud, and promote ethical practices

Trending Articles

  1. Novartis secures FDA approval for Rhapsido, the first oral BTKi treatment for chronic spontaneous urticaria Rhapsido (remibrutinib) offers a new targeted option for CSU patients, showing rapid symptom control and a favourable safety profile without lab monitoring, as Novartis expands its immunology portfolio
  2. Sharp appoints Samantha Wilson Jones as General Counsel Sharp Services has appointed Samantha Wilson Jones as General Counsel and Corporate Secretary of Sharp
  3. Trump warning: drugmakers must expand US manufacturing or face tariffs The president announced a new 100% tariff on branded medicines unless manufacturers are already building US plants
  4. PCI Pharma Services PCI Pharma Services: Your bridge between life-changing therapies and patients.
  5. You need to be a subscriber to read this article.
    Click here to find out more.
    From box to bedside: unlocking patient-centric care with connected packaging Pharmaceutical packaging is playing an increasing role in patient–centric care. The integration of smart 2D codes and connected digital platforms can provide a direct link between pharma manufacturers, healthcare providers and patients

Upcoming event

CPHI Frankfurt 2025

28–30 October 2025 | Exhibition | Frankfurt, Germany See all

You may also like

Manufacturing

Navigating SOE compliance: how to strengthen organic enforcement within your organisation

Part I of NSF’s webinar series explores strategies to meet rising regulatory demands, reduce fraud, and promote ethical practices
Manufacturing

Exploring Ireland’s thriving life sciences sector

NSF highlights its pivotal role in one of the world’s leading hubs for pharma and medical device manufacturing
Manufacturing

Quality control: the central pillar supporting peptide manufacturing

Amid the growing complexity and innovation in the field, this article explores how centralised quality control plays a pivotal role by ensuring both safety and consistency during custom peptide production
Regulatory

FDA lifts clinical hold on Neurizon’s NUZ-001 for ALS trial entry

The decision clears the path for NUZ-001 to join the HEALEY ALS Platform Trial later this year, advancing Neurizon’s lead therapy for amyotrophic lateral sclerosis and strengthening its regulatory and development pipeline
Distribution

Cold Chain Technologies launches “Smart Chain, Clear Gain” campaign to elevate digitalisation in pharma logistics

Leading temperature-controlled solution provider, Cold Chain Technologies (CCT), has unveiled its new campaign, Smart Chain, Clear Gain, aimed to redefine how pharmaceutical companies approach compliance, efficiency and value in cold chain logistics
Regulatory

Novartis secures FDA approval for Rhapsido, the first oral BTKi treatment for chronic spontaneous urticaria

Rhapsido (remibrutinib) offers a new targeted option for CSU patients, showing rapid symptom control and a favourable safety profile without lab monitoring, as Novartis expands its immunology portfolio
Regulatory

Pfizer strikes landmark deal with US government to lower drug prices

The agreement ensures Americans pay less for medicines while giving Pfizer tariff certainty and a clear pricing framework, enabling $70bn in US investment and a renewed focus on next-generation therapies in cancer, obesity, vaccines and immunology
Subscribe now